The Braintree, Mass.-based company posted losses of $6.5 million, or 12¢ per share, on sales of $234 million for the 3 months ended December 30, seeing the bottom line shrink 142.5% while sales grew 2.7% compared with the same period last year.
Adjusted to exclude one-time items, earnings per share were 62¢, well above the 44¢ consensus on Wall Street where analysts hoped to see sales of $226.9 million, which the company also topped.
“Our strategy is working and we have good momentum in our businesses, including revenue mix, gross margin and net income. The company moved forward with the complexity reduction initiative and the turnaround is on track. We are raising our fiscal 2018 adjusted earnings per share and free cash flow guidance,” CEO Chris Simon said in a press release.
The company released updated guidance for its fourth quarter and full fiscal year 2018, lifting its expectations for full year non-GAAP EPS from between $1.65 and $1.75 to between $1.80 and $1.90.
Shares in Haemonetics are up 8.8% so far today, at $66.05 as of 2:43 p.m. EST.
On June 4-5, DeviceTalks is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring, bringing you the best and brightest minds in the industry.
Heidi Dohse: Sr. Program Manager, Healthcare, Google, Founder, Tour de Heart Foundation, Acessa Health Inc. Michael J. Pederson: Senior Vice President, Cardiac Arrhythmias and Heart Failure Division, Abbott Hon. Melvin Carter: Mayor, Saint Paul Tim Philips: Compliance Officer, FDA’s Office of Medical Device and Radiological Health Operations Dr. Myriam J. Curet, MD, FACS: Chief Medical Officer, Intuitive Surgical
Take a look at our incredible line up of speakers and join us now.
Use the code "KEYNOTE" to save 15% on the cost of registration.